Plasmapp announced that it signed a supply contract worth 7 billion won for ACTILINK Vortex products, a plasma surface treatment solution, through the Kyushu Dental Expo held in Japan on the 17th.

This product was first launched at the Seoul International Dental Expo (SIDEX) held in May after receiving Japanese medical device certification in April 2023. At the SIDEX event, about 50 Japanese dental officials attended Plasmapp's exhibition booth. This is a product that people have expressed great interest in.

Based on the high interest of Japanese customers, we held a launch event in Japan in a consortium with Japanese distributors such as N Company and D Company at the Kyushu Dental Expo in Japan this June, and signed a supply contract worth a total of 7 billion won at the expo venue. A great achievement was achieved.

In particular, at this event, more than 100 Japanese dealers were interested in Plasmapp products and placed orders, and more than 200 dentists provided consultations, so experts in the Japanese market predicted that sales would accelerate in the future.

In the case of the plasma surface treatment solution, it is an innovative device that can improve biocompatibility during the treatment of global implants such as Straumann and Nobel, which are mainly used in Japan, and has attracted a lot of attention as a completely new technology that changes the existing method in Japan.

Youbong Lim, CEO of Plasmapp, said, “The results of the clinical efficacy evaluation with Harvard University in the U.S. announced in May were the biggest driving force behind our successful launch in the conservative Japanese market.” He added, “In reality, the Japanese medical device market is based on brand awareness and “Considering that the track record is important and the company is comprised mainly of North American/European companies, this contract is symbolic as Plasmapp’s brand awareness has begun to establish itself as a premium brand,” he said.

Following this contract for a surface treatment solution, Plasmapp showed its intention to accelerate entry into the Japanese market for its flagship product, sterilization solution.

The Japanese sterilization solution market is not only centered on premium companies such as W&H, MELAG, and SCICAN, but is also evaluated as a market that is more than 10 times larger than Korea in terms of size.

Plasmapp CEO Samjeong Yoon said, "Based on the distribution channel in Japan secured through this surface treatment machine and the suitability data in Japan secured through collaboration with GC, a large Japanese medical device company, we will hold the exhibition in Yokohama, Japan's largest dental fair held in September. “We are planning to launch a sterilization solution in Japan,” he said. “In particular, Japanese companies are showing high interest in FDA-certified sterilization solutions, and the sterilizer market is larger than the surface treatment market, so larger contracts are expected through the launch in September.” “It will happen,” he said.

(Source: http://www.bokuennews.com/news/article.html?no=230305 )